IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

SALVI, Annibale et

APPLICANT(S): al. **EXAMINER:**

Unassigned

SERIAL NO.:

Unassigned

GROUP ART UNIT:

Unassigned

FILED:

November 3, 2003

Attorney Docket No.: P-6320-US

FOR.:

BASIC SALT OF THIOCTIC ACID WITH L-CARNITINE

Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 C.F.R. §§1.56, 1.97 and 1.98, this Information Disclosure Statement includes Form PTO-1449:

| 1 🔀 | listing documents including patents, publications, and other information for consideration |
|------|--|
| | by the Examiner, copies of which are included with this information disclosure statement; |
| 2. 🗌 | listing documents including patents, publications and other information that have been |
| | previously cited or submitted to the Patent Office in prior application U.S. Serial No. |
| | , filed which is properly identified and relied on for an earlier effective |
| | filing date under 35 U.S.C. 120 for consideration by the Examiner; however, in accordance |
| | with 37 C.F.R. 1.98(d), copies of such documents are not included in this information |
| | disclosure statement; and/or |
| 3. 🔲 | listing other information for the Examiner's consideration which was cited in a |
| | communication from a foreign patent office in a counterpart foreign application, a copy of |
| | which is included with this information disclosure statement. |
| | |

The information herein cited is only in fulfillment of Applicant(s) duty of candor in disclosing all information brought to Applicant(s) attention. This submission does not represent that a search has APPLICANTS: FILED:

Page 2

SALVI, Annibale et al.

listed documents are material or constitute "prior art". If it should be determined that any of the listed documents do not constitute "prior art" under United States law, Applicant(s) reserve the right to present to the office the relevant facts and law regarding the appropriate status of such documents.

Applicant(s) further reserve(s) the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

In accordance with MPEP Sections 609 and 707.05(b), it is requested that each and every document cited (including any cited in applicant's specification which is not repeated on the attached Form PTO-1449) be given thorough consideration and that it be cited of record in the prosecution history of the present application by initialing on Form PTO-1449. Such initialing is requested even if the Examiner does not consider it to be prior art for any reason, or even if the Examiner does not believe that the guidelines for citation have been fully complied with. This is requested so that each document becomes listed on the face of the patent issuing on the present application and is evidence that the Examiner has considered the document.

This Information Disclosure Statement is being filed:

 \square

| 1) Within three (3) months of filing the subject Application or entry of the | | | | | | | | | |
|---|--|--|--|--|--|--|--|--|--|
| subject Application into the national stage or before mailing of the first Office Action on | | | | | | | | | |
| the merits of the subject Application or a request for continued examination thereof, | | | | | | | | | |
| whichever event occurs last pursuant to of 37 C.F.R §1.97 (b); or | | | | | | | | | |
| II) After the period specified in (I) but before the mailing date of either a final | | | | | | | | | |
| Official Action under 37 C.F.R §1.113 or a notice of allowance under 37 C.F.R §1.311 | | | | | | | | | |
| whichever occurs first and; | | | | | | | | | |
| 1. | | | | | | | | | |
| the Form PTO-1449 was either (i) cited in a communication from a foreign patent | | | | | | | | | |
| office in a counterpart foreign application not more than three (3) months prior to | | | | | | | | | |
| the filing of this Information Disclosure Statement or (ii) not cited in a | | | | | | | | | |
| communication from a foreign patent office in a counterpart foreign application, | | | | | | | | | |
| and, to the knowledge of the undersigned after making reasonable inquiry, not | | | | | | | | | |
| known to any individual designated in §1.56(c) more than three (3) months prior to | | | | | | | | | |
| the filing of this information disclosure statement; or | | | | | | | | | |

| SERIAL NO FILED: Page 3 |). : | |
|-------------------------------|-------------|--|
| | 2. | the undersigned hereby authorizes the Patent Office to charge the fee |
| | in the | e amount of \$180.00 under 37 C.F.R §1.17 (p) to Deposit Account 05-0649. |
| m) |) [| After the period in (I) and (II) but before the payment of the issue fee and, |
| | . 1. | The undersigned hereby states: |
| | • | a) |
| | | was cited in a communication from a foreign Patent Office in a counterpart |
| | | foreign application not more than three (3) months prior to the filing of this |
| | | Information Disclosure Statement; or |
| | | b) |
| | | was cited in a communication from a foreign patent office in a counterpart |
| | • | foreign application, and to the knowledge of the undersigned after making |
| ٠. | , | reasonable inquiry, no item of information contained in this Information |
| | | Disclosure Statement was known to any individual designated in 37 C.F.R. § |
| | | 1.56(c) more than three months prior to the filing of this Information |
| • | | Disclosure Statement; and |
| | 2 | The undersigned hereby authorizes the Patent Office to charge the |

Petition fee in the Amount of \$180.00 under 37 C.F.R §1.17 (p) to Deposit Account

SALVI, Annibale et al.

APPLICANTS:

05-0649.

APPLICANTS:

SALVI, Annibale et al.

SERIAL NO.: FILED:

Page 4

Except for issue fees payable under 37 C.F.R. §1.18, the Commissioner is hereby authorized by this paper to charge any additional fees during the entire pendency of this application including fees due under 37 C.F.R. §§1.16 and 1.17 which may be required, including any required extension of time fees, or credit any overpayment to Deposit Account No. 05-0649.

Respectfully submitted,

Caleb Pollack

Attorney for Applicant(s) Registration No. 37,912

Dated: November 3, 2003

Eitan, Pearl, Latzer & Cohen Zedek, LLP. 10 Rockefeller Plaza, Suite 1001

New York, New York 10020

Tel: (212) 632-3480 Fax: (212) 632-3490

| | | | | | | Patent a | nd Trad | Appro demari | ved for use the | PTO/SB/08. rough 10/31/99. OMB 0 DEPARTMENT OF COM | 651-(MME) |
|---|---------------|--|---------------------------------|-------------|---|----------------------------|----------------|------------------------------|---------------------------------------|--|---------------|
| er the Pap | · · | | | | re required to | respond to a collecti | on of in | formati | on unless it dis | splays a valid OMB contro | ol nun |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT | | | | | Compl te if Known | | | | | <u>, , , </u> | |
| | | | | | Application Number Unassigned Filing Date First Named Inv ntor SALVI, Ann Group Art Unit | | | ed | | | |
| | | | | | | | | | | | SALVI, An |
| | | | | | | | | | | | |
| | | | | | | | | | (use a | s many s | heets as n |
| Sheet | | of | | | | Attorney Docket Number | | ber | P-6320-US | | |
| | | | | | ····· | | | | | | |
| | 7 · | 1 115 | | | S. PATEN | T DOCUMEN | rs | | | 1.0 | |
| kaminer | Cite | U.S. Patent Document | | Name of P | atentee or Applicar | nt D | | Publication of | AALICIG LZCICAGIIL | | |
| Examiner Initials* | No.1 | Number Kind Code ² (if known) | | | Name of Patentee or Applicant of Clted Document | | | Cited Document MM-DD-YYYY | | Passages or Relevant Figures Appear | |
| | A | 5,916,912 | 2 | | AMES, Bruce | N. et al. | Jı | une 29, | 1999 | | |
| | | ļ | | | | | | | | | |
| | ļ | ļ | | | | <u> </u> | | | | | |
| | - | ļ | | | | | | | | ļ <u></u> | |
| | | | | | | | | | | | |
| . • . | | | - · · · · · · · · · · · · · · · | | | | | | | | • |
| | | | - | | | | - | <u> </u> | | · · · · · · · · · · · · · · · · · · · | |
| | | | | | | | | | | | |
| | | | | | , | | | | | | |
| | ļ | ļ | · | | | | | | · · · · · · · · · · · · · · · · · · · | | |
| | | | | | | | | | | | |
| | | | | | | | -+ | | | | |
| | | † | - | : | | | | | | | |
| | · | | | | | | | | | | |
| | | | | | | | | | | | |
| | _ | | | | | | | | | | |
| | - | + | | | | | | | | | |
| | <u> </u> | <u> </u> | | · | | | | | | | |
| | | | | FORE | IGN PAT | ENT DOCUME | NTS | | | | |
| | | Foreig | nPatent Doc | ument | Name | | | NAME OF FRANCISCO | | Pages, Columns, Lines, | T |
| aminer tials* | Cite No. 1 | Office ³ Number ⁴ (if known) | | | Name of Patentee or Applicant of Cited Document | | Cited Document | | cument | Where Relevant Passages or Relevant Figures Appear | T |
| | В | WIPO | WO 02/30919 | | | RIO CHIMICO NALE S.P.A. | April 1 | 8, 2002 | | | |
| | С | WIPO | WO 02/30917 | | · · · · · · · · · · · · · · · · · · · | RIO CHIMICO NALE S.P.A | April 1 | 8, 2002 | | | |
| | ם | WIPO | WO 02/30918 | | LABORATOF INTERNAZIO | RIO CHIMICO NALE S.P.A | April 1 | 8, 2002 | | | Ó |
| | | | | | | | | | | | |

| | , | T = . | | | IGN PATENT DOCUME | -1110 | | |
|-----------------------|---------------|-------|----------------|---------------------|--|--|--|-------------|
| Examiner Initials* | Cite No. 1 | • | | d Code ⁵ | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document MM-DD-YYYY | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T |
| | В | WIPO | WO 02/30919 | | LABORATORIO CHIMICO INTERNAZIONALE S.P.A. | April 18, 2002 | | |
| | С | WIPO | WO 02/30917 | | LABORATORIO CHIMICO INTERNAZIONALE S.P.A | April 18, 2002 | | ַ |
| | D | WIPO | WO 02/30918 | | LABORATORIO CHIMICO INTERNAZIONALE S.P.A | April 18, 2002 | | [|
| | E | FR | 4512 | | CENTRE D'ETUDE E DE REALISATIONS THERAPEUTIQUES (C.E.R.E.T.) | November 21, 1966 | | |
| | ļ | | | | | | | [|
| | ļ | 5 | | | | | | |
| | <u> </u> | | | | | | | _ [|
| | <u> </u> | 4 | <u> </u> | | | | | _[[|
| | ļ | | <u> </u> | | | | | _ [[|
| | | | 1 | | | <u> </u> | 1 | |